What were the efficacy outcomes for topical roflumilast in Phase 3 clinical trials?

Featuring Mark Lebwohl, MD | Senior Clinical Advisor | Professor and Chairman Emeritus of the Kimberly and Eric J. Waldman Department of Dermatology Dean for Clinical Therapeutics at the Icahn School of Medicine, Mount Sinai New York, NY | Published August 30, 2022